RxDoctor Payments Data

Darryl Reaume, DO

Urology · Clarkston, MINPI 1982668448

Payments from drug & device makers

$7,921in general payments, 2019–2025

Across 323 payments — averaging $24.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$1K
  • Teleflex LLC$1K
  • Procept Biorobotics Corporation$755
  • Rochester Medical Corporation$424
  • Coloplast$370
  • Johnson & Johnson$305
  • plus $3K from 40 others

What the payments were for

  • Travel & lodging$6809%
  • Food & beverage$6,60483%
  • Education$6378%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,921 in reported general payments places this provider in the 70th percentile of 400 urology providers in Michigan.

See all urology providers in Michigan

Medicare billing

Part B allowed, 2024
$172,992
Medicare patients
468
Services billed
2,064

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XtandiEnzalutamide12$170,012
OrgovyxRelugolix46$118,775
MyrbetriqMirabegron84$66,136
GemtesaVibegron59$51,621
XyostedTestosterone Enanthate26$30,019
Mirabegron ErMirabegron23$17,064
Tamsulosin Hcl641$12,028
Finasteride628$11,112
Testosterone25$10,921
Potassium Citrate ErPotassium Citrate63$8,487
Alfuzosin Hcl ErAlfuzosin Hcl159$5,625
Estradiol44$3,601
Dutasteride66$3,259
Oxybutynin Chloride ErOxybutynin Chloride113$2,788
Bethanechol Chloride31$2,365

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncXtandi, Myrbetriq$1,491$236,14796 claims
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$293$170,396105 claims
Antares Pharma, Inc.Xyosted$211$30,01926 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 400 urology providers in Michigan.

Other urology in Clarkston

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →